{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:50:57Z","timestamp":1783529457662,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272807"],"award-info":[{"award-number":["82272807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint blockade targeting the PD-1\/PD-L1 axis has revolutionized cancer therapy, yet the frequent emergence of resistance limits its clinical efficacy. Elucidating the mechanisms underlying resistance and developing effective strategies remain critical challenges in tumor immunotherapy. This study identifies kinase suppressor of Ras 2 (KSR2) as a driver of resistance to anti-PD-1 therapy in lung cancer. Transcriptomic analysis of an anti-PD-1-resistant mouse model and public clinical datasets revealed upregulation of KSR2 in resistant tumors. In vivo functional studies demonstrated that KSR2 overexpression is sufficient to confer resistance, while its knockdown resensitizes tumors to PD-1 blockade. Mechanistically, KSR2 functions as a central metabolic checkpoint, driving profound glucose metabolic reprogramming in cancer cells by enhancing glucose uptake, potentiating the Warburg effect, promoting lactate accumulation, and disrupting the tricarboxylic acid cycle. This metabolic reprogramming was subsequently associated with an immunosuppressive tumor microenvironment, characterized by reduced infiltration and impaired function of CD8\u207a T cells, alongside an enrichment of regulatory T cells. These findings suggest that KSR2 plays a role in modulating immunotherapy response, indicating a potential link between tumor metabolism and immune evasion. KSR2 emerges as a candidate target for further exploration in overcoming anti-PD-1 resistance.<\/jats:p>","DOI":"10.1007\/s00262-026-04394-z","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:46:28Z","timestamp":1776779188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KSR2 functions as a metabolic checkpoint for anti-PD-1 resistance by reprogramming glucose metabolism"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1685-3226","authenticated-orcid":false,"given":"Yuli","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-9221","authenticated-orcid":false,"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"7834","key":"4394_CR1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/d41586-020-03152-0","volume":"587","author":"H Brody","year":"2020","unstructured":"Brody H (2020) Lung cancer. Nature 587(7834):S7. https:\/\/doi.org\/10.1038\/d41586-020-03152-0","journal-title":"Nature"},{"issue":"1","key":"4394_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4394_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4394_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/jco.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon JHellmann MD (2022) First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol 40(6):586\u2013597. https:\/\/doi.org\/10.1200\/jco.21.01497","journal-title":"J Clin Oncol"},{"issue":"1","key":"4394_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD et al (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer 22(1):40. https:\/\/doi.org\/10.1186\/s12943-023-01740-y","journal-title":"Mol Cancer"},{"key":"4394_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, Shi ZD, Wei LY et al (2023) Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist Updat 66:100907. https:\/\/doi.org\/10.1016\/j.drup.2022.100907","journal-title":"Drug Resist Updat"},{"key":"4394_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang TChen L (2022) Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol 40:45\u201374. https:\/\/doi.org\/10.1146\/annurev-immunol-070621-030155","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"4394_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","volume":"15","author":"J Hu","year":"2023","unstructured":"Hu J, Zhang L, Xia H et al (2023) Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med 15(1):14. https:\/\/doi.org\/10.1186\/s13073-023-01164-9","journal-title":"Genome Med"},{"issue":"1","key":"4394_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12943-024-02165-x","volume":"23","author":"S Liu","year":"2024","unstructured":"Liu S, Zhang X, Wang W et al (2024) Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Mol Cancer 23(1):261. https:\/\/doi.org\/10.1186\/s12943-024-02165-x","journal-title":"Mol Cancer"},{"issue":"1","key":"4394_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13046-023-02827-6","volume":"42","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wang H, Liu Q et al (2023) LncRNA CCAT1 facilitates the progression of gastric cancer via PTBP1-mediated glycolysis enhancement. J Exp Clin Cancer Res 42(1):246. https:\/\/doi.org\/10.1186\/s13046-023-02827-6","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"4394_CR11","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.7150\/thno.95748","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang J, Jia W, Zhou X et al (2024) CBX4 suppresses CD8(+) T cell antitumor immunity by reprogramming glycolytic metabolism. Theranostics 14(10):3793\u20133809. https:\/\/doi.org\/10.7150\/thno.95748","journal-title":"Theranostics"},{"issue":"2","key":"4394_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, Koyama S, Itahashi K et al (2022) Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell 40(2):201-218.e9. https:\/\/doi.org\/10.1016\/j.ccell.2022.01.001","journal-title":"Cancer Cell"},{"issue":"6","key":"4394_CR13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.cmet.2021.04.001","volume":"33","author":"Y Liu","year":"2021","unstructured":"Liu Y, Liang G, Xu H et al (2021) Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab 33(6):1221-1233.e11. https:\/\/doi.org\/10.1016\/j.cmet.2021.04.001","journal-title":"Cell Metab"},{"issue":"4","key":"4394_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.cell.2013.09.058","volume":"155","author":"LR Pearce","year":"2013","unstructured":"Pearce LR, Atanassova N, Banton MC et al (2013) KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation. Cell 155(4):765\u2013777. https:\/\/doi.org\/10.1016\/j.cell.2013.09.058","journal-title":"Cell"},{"issue":"1","key":"4394_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao X, Liang Y, Chang H et al (2024) Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther 9(1):13. https:\/\/doi.org\/10.1038\/s41392-023-01690-3","journal-title":"Signal Transduct Target Ther"},{"issue":"7839","key":"4394_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","volume":"588","author":"X Liu","year":"2020","unstructured":"Liu X, Bao X, Hu M et al (2020) Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature 588(7839):693\u2013698. https:\/\/doi.org\/10.1038\/s41586-020-2911-7","journal-title":"Nature"},{"issue":"1","key":"4394_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00361-9","volume":"10","author":"C Gao","year":"2022","unstructured":"Gao C, Wang SW, Lu JC et al (2022) KSR2-14-3-3\u03b6 complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma. Biomark Res 10(1):25. https:\/\/doi.org\/10.1186\/s40364-022-00361-9","journal-title":"Biomark Res"},{"issue":"8","key":"4394_CR18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL et al (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21(8):938\u2013945. https:\/\/doi.org\/10.1038\/nm.3909","journal-title":"Nat Med"},{"issue":"W1","key":"4394_CR19","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z et al (2020) TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 48(W1):W509-w514. https:\/\/doi.org\/10.1093\/nar\/gkaa407","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"4394_CR20","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru B, Wong CN, Tong Y et al (2019) TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics 35(20):4200\u20134202. https:\/\/doi.org\/10.1093\/bioinformatics\/btz210","journal-title":"Bioinformatics"},{"issue":"5","key":"4394_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.cmet.2009.09.010","volume":"10","author":"DL Costanzo-Garvey","year":"2009","unstructured":"Costanzo-Garvey DL, Pfluger PT, Dougherty MK et al (2009) KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab 10(5):366\u2013378. https:\/\/doi.org\/10.1016\/j.cmet.2009.09.010","journal-title":"Cell Metab"},{"issue":"9","key":"4394_CR22","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s42255-024-01092-x","volume":"6","author":"AF McGettrick","year":"2024","unstructured":"McGettrick AF, Bourner LA, Dorsey F CO\u2019Neill LAJ (2024) Metabolic messengers: itaconate. Nat Metab 6(9):1661\u20131667. https:\/\/doi.org\/10.1038\/s42255-024-01092-x","journal-title":"Nat Metab"},{"issue":"1","key":"4394_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cmet.2018.09.003","volume":"29","author":"J Dom\u00ednguez-Andr\u00e9s","year":"2019","unstructured":"Dom\u00ednguez-Andr\u00e9s J, Novakovic B, Li Y et al (2019) The itaconate pathway is a central regulatory node linking innate immune tolerance and trained immunity. Cell Metab 29(1):211-220.e5. https:\/\/doi.org\/10.1016\/j.cmet.2018.09.003","journal-title":"Cell Metab"},{"issue":"5","key":"4394_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s42255-022-00577-x","volume":"4","author":"F Chen","year":"2022","unstructured":"Chen F, Elgaher WAM, Winterhoff M et al (2022) Citraconate inhibits ACOD1 (IRG1) catalysis, reduces interferon responses and oxidative stress, and modulates inflammation and cell metabolism. Nat Metab 4(5):534\u2013546. https:\/\/doi.org\/10.1038\/s42255-022-00577-x","journal-title":"Nat Metab"},{"key":"4394_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cytogfr.2022.11.001","volume":"68","author":"L Ye","year":"2022","unstructured":"Ye L, Jiang YZhang M (2022) Crosstalk between glucose metabolism, lactate production and immune response modulation. Cytokine Growth Factor Rev 68:81\u201392. https:\/\/doi.org\/10.1016\/j.cytogfr.2022.11.001","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"4394_CR26","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.it.2022.10.005","volume":"43","author":"EL Apostolova PPearce","year":"2022","unstructured":"Apostolova PPearce EL (2022) Lactic acid and lactate: revisiting the physiological roles in the tumor microenvironment. Trends Immunol 43(12):969\u2013977. https:\/\/doi.org\/10.1016\/j.it.2022.10.005","journal-title":"Trends Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04394-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:46:29Z","timestamp":1776779189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04394-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4394"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04394-z","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were approved by the Comparative Medicine Center of Eastern Theater General Hospital and conducted in accordance with the International Guiding Principles for Biomedical Research Involving Animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"151"}}